CTLT FINAL DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Catalent, Inc. Investors with Losses to Secure Counsel Before Important April 25 Deadline in Securities Class Action – CTLT Apr 22, 2023 12:35PM
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Catalent, Tesla, DLocal, and Cognyte and Encourages Investors to Contact the Firm Apr 17, 2023 09:00PM
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Catalent, Tesla, DLocal, and Cognyte and Encourages Investors to Contact the Firm Mar 27, 2023 09:00PM
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Catalent, Tesla, DLocal, and Cognyte and Encourages Investors to Contact the Firm Mar 17, 2023 09:00PM
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Catalent, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CTLT Mar 16, 2023 12:20PM


Jan 9, 2023 07:32AM Avantor (AVTR) Enters Multi-Year Supply and Services Agreement with Catalent (CTLT)
Jan 9, 2023 07:30AM Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement
Jan 5, 2023 08:31AM Sarepta (SRPT) and Catalent (CTLT) Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Jan 5, 2023 08:30AM Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Nov 3, 2022 08:05AM Exelixis (EXEL) and Catalent (CTLT) Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Nov 3, 2022 08:00AM Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
Jan 19, 2022 07:30AM ElevateBio Announces Andrew Sandford Joins as President of ElevateBio BaseCamp
Sep 8, 2020 08:08AM Exelixis (EXEL) and Catalent (CTLT) Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag Bioconjugation Technology
Jun 19, 2019 07:01AM Catalent (CTLT) Reports Acquisition of Bristol-Myers Squibb (BMY) Manufacturing Facility in Anagni, Italy
Jun 19, 2019 06:59AM Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
Jun 19, 2019 06:59AM Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
Jun 20, 2016 09:30AM Pre-Open Stock Movers 06/20: (LPTN) (FATE) (CERS) Higher (more...)
May 14, 2015 08:05AM Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 14, 2015 08:05AM Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 5, 2015 04:01PM Catalent, Inc. Reports Third Quarter Fiscal Year 2015 Results